- You can view the full Johnson & Johnson Ratings Report.
The Dow Jones Industrial Average ( ^DJI) is trading up 53 points (+0.4%) at 12,890 as of Thursday, Mar 8, 2012, 11:40 a.m. ET. During this time, 230.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio sits at 2,167 issues advancing vs. 709 declining with 106 unchanged. The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ), which is sporting a 60-cent gain (+0.9%) bringing the stock to $64.90. This single gain is lifting the Dow Jones Industrial Average by 4.54 points or roughly accounting for 8.6% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 5.2 million shares traded vs. an average daily trading volume of 10.7 million shares. Johnson & Johnson has a market cap of $177.51 billion and is part of the health care sector and drugs industry. Shares are down 2% year to date as of Wednesday's close. The stock's dividend yield sits at 3.5%. Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. The company has a P/E ratio of 18.4, above the average drugs industry P/E ratio of 15.9 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.